secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001193125-26-104102
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics reports FY2025 loss from ops $36.1M; cash $31.8M into 2027
-------------------------------------------------------------------------------

- Collaboration revenue $7.7M for FY2025, flat YoY; Q4 2025 revenue $2.5M vs $0 in Q4 2024.
- R&D expenses $28.5M in FY2025, down from $57.5M in FY2024; G&A $13.8M vs $18.5M, driven by restructuring.
- Loss from operations $36.1M for FY2025 vs $73.0M in FY2024.
- Cash, cash equivalents and marketable securities $31.8M as of Dec 31, 2025; expected to fund milestones into 2027.
- Initial clinical data for BDC-4182 Phase 1 study (CLDN18.2) expected in Q3 2026; step-up dosing added to protocol.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000119312526104102/0001193125-26-104102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000119312526104102/bolt-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-104102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer